Showing results (1-10 of 153) with videos related to
Sort By:
Pageof 16
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 15, 2014
[Radiation therapy for malignant lymphoma]Isao Asakawa, Tetsuro Tamamoto, Masatoshi HasegawaBrachytherapy|December 3, 2014
Urethral toxicity after LDR brachytherapy: experience in JapanNobumichi Tanaka, Isao Asakawa, Masatoshi Hasegawa, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|September 25, 2019
Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in JapanNobumichi Tanaka, Isao Asakawa, Masatoshi Hasegawa, et al.Urology|April 21, 2009
Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancerNobumichi Tanaka, Kiyohide Fujimoto, Yoshihiko Hirao, et al.Radiation Oncology (London, England)|June 3, 2014
The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitionsNobumichi Tanaka, Isao Asakawa, Emiko Katayama, et al.Radiation Oncology (London, England)|February 1, 2013
Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapyNobumichi Tanaka, Isao Asakawa, Satoshi Anai, et al.BMC Urology|September 15, 2012
Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancerNobumichi Tanaka, Isao Asakawa, Kiyohide Fujimoto, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 17, 2009
[Application of PET in radiation oncology]Masatoshi Hasegawa, Fumiaki Uto, Isao Asakawa, et al.BMC Research Notes|October 27, 2014
Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case reportShunta Hori, Nobumichi Tanaka, Isao Asakawa, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|January 6, 2009
Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patientsNobumichi Tanaka, Isao Asakawa, Hideaki Kondo, et al.Pageof 16